NCT06712849 Noninvasive Brain Stimulation in Adult Amblyopia
| NCT ID | NCT06712849 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Midwestern University |
| Condition | Amblyopia |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-05-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-05-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this randomized controlled trial is to investigate the effectiveness of non-invasive brain stimulation in treating adults with amblyopia. The main questions it aims to answer are: 1. What are the effects of non-invasive brain stimulation on neuronal plasticity in the visual cortex of adults with amblyopia, and does it produce lasting changes? 2. Do cumulative sessions of non-invasive brain stimulation influence neural plasticity and higher-order visual functions in adults with amblyopia? The investigators hypothesize that non-invasive brain stimulation will show a positive cumulative effect after five (5) consecutive days of stimulation on visual perception and function in adults with amblyopia. Participants will be randomized into one of two treatment groups: 1. High-frequency transcranial random noise stimulation (hf-tRNS). 2. Sham stimulation. Researchers will compare baseline measurements of crowded visual acuity, contrast sensitivity, stereoacuity, phosphene thresholds, global motion perception, form pattern recognition and pattern-reversal visual evoked potentials (VEPs) to post-treatment measurements for each group.
Eligibility Criteria
Inclusion Criteria: * Adults between 18 and 55 years of age * Formal diagnosis of amblyopia in one or both eyes of any etiology Exclusion Criteria: * History of optic nerve disease, including glaucoma and optic neuritis * History of neurological conditions, including demyelinating disease or stroke * Presence of metal or electronic implants in or on the body, including pacemakers * Taking medications that can affect normal neurological function, including antipsychotics, antiepileptics, and opioids
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06712849 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Amblyopia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06712849 currently recruiting?
Yes, NCT06712849 is actively recruiting participants. Contact the research team at achakr@midwestern.edu for enrollment information.
Where is the NCT06712849 trial being conducted?
This trial is being conducted at Downers Grove, United States.
Who is sponsoring the NCT06712849 clinical trial?
NCT06712849 is sponsored by Midwestern University. The trial plans to enroll 60 participants.